Alzheimer's Clinical Trials in Las Vegas

View 19 new treatments for Alzheimer's in Las Vegas, NV, and other areas near me, such as Henderson. Every day, Power helps hundreds of alzheimers patients connect with leading medical research.
View 18 trials in Las Vegas
Filter (18)

AVP-786 for Alzheimer's-related Agitation

Avanir Clinic, Las Vegas + 2 more

This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Semaglutide for Early Alzheimer's Disease

Novo Nordisk Clinic, Las Vegas + 1 more

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Clinical Transparency (Dept. 2834)
Study Director

ALZ-801 for Early Alzheimer's Disease

Alzheon Clinic, Las Vegas + 1 more

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Susan Abushakra, MD
Principal Investigator

KarXT for Alzheimer's-Related Psychosis

Karuna Clinic, Las Vegas + 1 more

This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Paul Yeung, MD, MPH
Study Director

Remternetug for Alzheimer's Disease

Eli Lilly Clinic, Las Vegas + 1 more

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Donanemab for Early Alzheimer's Disease

Eli Lilly Clinic, Las Vegas + 2 more

This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

AR1001 for Alzheimer's Disease

AriBio Clinic, Las Vegas + 1 more

This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Sharon Sha, MD, MS
Principal Investigator

Remternetug for Alzheimer's Disease

Eli Lilly Clinic, Las Vegas + 1 more

This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Escitalopram for Agitation in Alzheimer's Disease

Research Clinic, Las Vegas + 1 more

The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
Waitlist
Phase 3
Est. 6 - 12 Weeks
Constantine Lyketsos, MD, MHS
Study Chair

Donanemab for Alzheimer's Disease

Eli Lilly Clinic, Las Vegas + 4 more

This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 2

Frequently Asked Questions

How much do alzheimer's clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do alzheimer's clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across alzheimers trials in Las Vegas, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for alzheimers patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Las Vegas is research being conducted for alzheimer's?

The Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas is conducting Alzheimer's clinical trials. Additionally, Las Vegas Medical Research is involved in these trials, with approximately 10 trials ongoing as of 2024.

What promising new drugs are being tested?

In Las Vegas, Alzheimer's research is focusing on categories like Monoclonal Antibodies and Radiopharmaceuticals. Notable treatments being studied include Donanemab, Semaglutide, and various radiopharmaceuticals like Amyvid and Neuraceq.